This study is being done to answer the following questions:
If you have high risk prostate cancer, a low gene risk score and plan to receive radiation therapy, is a shorter hormone therapy treatment as effective at controlling your cancer compared to the usual 24-month hormone therapy treatment?
If you have high risk prostate cancer, a high gene risk score and plan to receive radiation therapy, does adding a new hormone therapy drug to the usual treatment increase the length of time without your prostate cancer spreading as compared to the usual treatment?
We are doing this study because we want to find out if these approaches are better, similar, or worse than the usual approach for your type of prostate cancer. The usual approach is defined as the care most people get for prostate cancer.